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Hypoxia is a key factor contributing to the progression of human neoplasias and to the development of resistance to chemotherapy.
BNIP3 is a proapoptotic member of the Bcl-2 protein family involved in hypoxia-induced cell death. We evaluated the expression and
methylation status of BNIP3 gene to better understand the role of epigenetic alteration of its expression in haematopoietic tumours.
Methylation of the region around the BNIP3 transcription start site was detected in four acute lymphocytic leukaemia, one multiple
myeloma and one Burkitt lymphoma cell lines, and was closely associated with silencing the gene. That expression of BNIP3 was
restored by treatment with 5-aza20-deoxycytidine (5-aza-dC), a methyltransferase inhibitor, which confirmed the gene to be
epigenetically inactivated by methylation. Notably, re-expression of BNIP3 using 5-aza2-dC also restored hypoxia-mediated cell death
in methylated cell lines. Acetylation of histone H3 in the 50 region of the gene, which was assessed using chromatin
immunoprecipitation assays, correlated directly with gene expression and inversely with DNA methylation. Among primary tumours,
methylation of BNIP3 was detected in five of 34 (15%) acute lymphocytic leukaemias, six of 35 (17%) acute myelogenous leukaemias
and three of 14 (21%) multiple myelomas. These results suggest that aberrant DNA methylation of the 50 CpG island and histone
deacetylation play key roles in silencing BNIP3 expression in haematopoietic tumours.
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As compared to normal tissues, solid tumours are poorly
oxygenated and thus contain regions of hypoxia, which provide
a physiologically selective pressure for expansion of cells that have
acquired antiapoptotic potential (Graeber et al, 1996). Haemato-
poietic tumours growing in bone marrow are also in a hypoxic
environment, and several lines of evidence suggest that, like solid
tumours, they are dependent on vascular support (Aguayo et al,
1999). Indeed, angiogenesis is an important determinant of tumour
cell survival under hypoxic conditions, and expression of VEGF is
known to be upregulated in acute and chronic myelogenous
leukaemia (Aguayo et al, 1999; Mayerhofer et al, 2002). Little is
known, however, about how haematopoietic tumour cells escape
apoptosis normally induced by hypoxic stress.
First identified via its interaction with adenovirus E1B 19-kDa
and Bcl-2, BNIP3 is one of the Bcl-2 homology 3 (BH3)-only
subfamily of Bcl-2 proteins, which display proapoptotic activity
(Boyd et al, 1994). Forced expression of BNIP3 induces cell death
characterised by localisation of the protein at the mitochondria,
opening of the permeability transition pore, loss of membrane
potential and production of reactive oxygen species (Regula et al,
2002; Vande Velde et al, 2000). This form of cell death is
independent of cytochrome c release from mitochondria and
caspase activation (Vande Velde et al, 2000). Expression of BNIP3,
which is dramatically increased in response to hypoxia, is
regulated in part by hypoxia-inducible factor-1 (HIF-1), a
heterodimeric transcription factor comprised of an oxygen-
regulated a subunit (HIF-1a) and a stale nuclear factor (HIF-1b/
ARNT), and known to be a mediator of the hypoxic response
(Semenza, 1999). Under normoxic conditions, HIF-1a is rapidly
degraded by proteasome after being targeted for ubiquitination
(Maxwell et al, 1999). Under hypoxic conditions, degradation of
HIF-1a is suppressed, and expression of BNIP3 is induced.
There is now compelling evidence that in many human
neoplasias, epigenetic alteration plays a key role in silencing genes
involved in cell cycle regulation, apoptosis, metastasis and immune
responses (Jones and Laird, 1999; Toyota and Issa, 1999; Baylin
et al, 2001). For example, DNA methylation and histone
deacetylation are known to be responsible for silencing various
genes in neoplasias (Bird and Wolffe, 1999; Magdinier and Wolffe,
2001; Nguyen et al, 2001). However, although changes in DNA
methylation are known to play a role in leukaemogenesis (Melki
and Clark, 2002), little is known about epigenetic alteration of
genes involved in hypoxia. To clarify the molecular mechanism
of the resistance to hypoxia-induced apoptosis in haemato-
poietic tumours, we examined BNIP3 expression in a panel of
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shaematopoietic tumour cell lines and evaluated the DNA methyla-
tion and histone acetylation status of the 50 CpG island of the
BNIP3 gene. Our results indicate that aberrant methylation and
histone deacetylation of the region around the transcription start
site is closely associated with the loss of BNIP3 expression, and
that methyltransferase inhibitors restore expression. The use of
such drugs may thus represent an effective new approach to the
treatment of haematopoietic tumours.
MATERIALS AND METHODS
Cell lines and specimens
We used 14 acute lymphocytic leukaemia (ALL) cell lines (BALL1,
Jurkat, CCRF-CEM, CCRF-SB, CCRF-HSB2, Molt4, SupT1, PEER,
TALL1, Molt3, TOM1, LB804ALL, NALM21 and NAGL1), four
multiple myeloma cell lines (KMS12-PE, RPMI8226, HS-Sultan and
KHM1B), two Burkitt lymphoma cell lines (Daudi and Raji) and
one myeloid leukaemia cell line (K562). All these cells were
cultured in appropriate medium. In addition, we analysed 34
primary ALL, 35 primary acute myeloid leukaemia (AML) and 14
primary multiple myeloma specimens, as described previously
(Toyota et al, 2001; Shen et al, 2003).
DNA was extracted from cells and tissue samples using the
phenol/chloroform extraction method; total RNA was extracted
using ISOGEN (Nippon Gene, Japan) according to the manufac-
turer’s instructions. To analyse restoration of BNIP3 expression,
SupT1, PEER, TALL1, Raji and KHM1B cells were incubated for
72h with 1mM 5-aza-20-deoxycytidine (5-aza-dC) (SIGMA, St
Louis, MO, USA). SupT1 cells were treated with 0.2mM 5-aza-dC,
300nM trichostatin A (TSA) or both.
Reverse transcription (RT)–PCR
Total RNA (5mg) was reverse-transcribed using Superscript III
(Invitrogen, Carlsbad, CA, USA) to prepare first-strand cDNA. The
primer sequences and PCR parameters used are shown in Table 1.
Controls consisted of RNA treated identically but without the
addition of reverse transcriptase and are labelled as RT . The
integrity of the cDNA was confirmed by amplifying GAPDH as
described previously (Suzuki et al, 2000). Samples (10ml) of
amplified product were then subjected to 2.5% agarose gel
electrophoresis and stained with ethidium bromide.
Real-time PCR was carried out using an ABI Prism 7000
(Applied Biosystems, Foster City, CA). Accumulation of PCR
product was measured in real time as an increase in SYBR green
fluorescence and analysed using ABI Prism 7000 SDS Software
(Applied Biosystems). Standard curves relating initial template
copy number to fluorescence and amplification cycle were
generated using the amplified PCR product as a template, and
were then used to calculate the mRNA copy number in each
sample. The ratios of the intensities of the BNIP3 and GAPDH
signals were considered to be a relative measure of the BNIP3
mRNA level in each specimen.
Western blot analysis
Cells were lysed in ice-cold Tris buffer (20mM Tris, pH 7.5).
containing 137mM NaCl, 2mM EDTA, 1% Triton X, 10% glycerol,
50mM NaF, 1mM DTT and a protease inhibitor cocktail (Roche
Applied Science, Mannheim, Germany). Samples (20mg) of the cell
lysate were then subjected to 10% SDS–PAGE, after which the
resolved proteins were transferred to Immobilon-P membranes
(Millipore, Bedford, MA). After blocking with 5% nonfat milk and
0.1% Tween-20 in Tris-buffered saline, the membranes were
probed with anti-HIF-1a (Cell Signaling, Beverly, MA, USA) and
anti-BNIP3 mouse monoclonal antibodies (Abcam, Cambridge,
UK). The blots were then visualised using enhanced chemilumi-
nescence (Amersham, Bucks, UK).
Bisulphite treatment
For bisulphite-PCR, genomic DNA was initially treated with
sodium bisulphite (SIGMA) as described previously (Clark et al,
1994). DNA (2mg) was denatured for 10min in 2 M NaOH at 371C
before addition of 30mlo f1 0 m M hydroquinone (SIGMA) and
520mlo f3 M sodium bisulphite (pH 5.0). The mixture was then
incubated for 16h at 501C. The resultant modified DNA was
purified using a Wizard DNA Purification System (Promega,
Madison, WI, USA), after which it was again treated with NaOH
and precipitated. Finally, the DNA precipitate was resuspended in
20ml of water and stored at  201C until used.
Combined bisulphite restriction analysis
Combined bisulphite restriction analysis (COBRA), a semiquanti-
tative methylation analysis, was carried out as described previously
(Xiong and Laird, 1997). PCR was performed in a 50-ml volume
containing 1 PCR buffer (67mM Tris–HCl, pH 8.8, 16.6mM
(NH4)2SO4, 6.7mM MgCl2 and 10mM b-mercaptoethanol),
0.25mM dNTP mixture, 0.5mM each primer and 1.0U of Hot Start
Taq polymerase (TaKaRa, Tokyo, Japan). PCR was then carried
out using the primer sequences and conditions listed in Table 1.
Primers were designed based on the nucleotide sequences obtained
from Genbank (AL162274). In total, 20ml of PCR product were
digested with AfaI (TaKaRa) and precipitated with ethanol, after
Table 1 Primer sequences for BNIP3 analysis
Annealing 1C (cycles) Size (bp)
COBRA F: 50-TTYGGTYGGAGGAATTTATAGGGTAG-30 58(3), 56(4), 54(5), 52(26) 156
R: 50-CCCTCRCCCACCRCAAAAC-30
Bisulphite-sequencing F: 50-GATATGGYGTTAGAGGGTAATTG-30 58(3), 56(4), 54(5), 52(26) 294
R: 50-CCCTCRCCCACCRCAAAAC-30
RT–PCR F: 50-CCACCTCGCTCGCAGACACCAC-30 66(3), 64(4), 62(5), 60(23) 317
R: 50-GAGAGCAGCAGAGATGGAAGGAAAAC-30
Real-time PCR F: 50-GGACAGAGTAGTTCCAGAGGCAGTTC-30 60 (40) 90
R: 50-GGTGTGCATTTCCACATCAAACAT-30
ChIP
BNIP3 F: 50-CCGCGCCGCCTCCTCCGCCTCAC-30 70 (35) 159
R: 50-GCTCCGACCTCCGCTTTCCCACCGCC-30
GAPDH F: 50-TCGGTGCGTGCCCAGTTGAACC-30 62 (35) 246
R: 50-ATGCGGCTGACTGTCGAACAGGAG-30
Y¼Co rT ,R¼A or G; ChIP¼Chromatin immunoprecipitation; GAPHD¼glyceraldehydes-3 phosphate dehydrogenase; COBRA¼combined bisulphite restriction analysis.
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swhich the DNA was subjected to 3% Nusieve gel electrophoresis
and stained with ethidium bromide. The intensity of the
methylated alleles was calculated by densitometry using a Lane
and Spot Analyzer 6.0 (Atto, Tokyo, Japan).
Bisulphite-sequencing
For bisulphite-sequencing, the PCR products obtained with
Bisulphite-PCR were cloned into pCR4.0 vector using a TOPO-
TA cloning kit (Invitrogen), after which 10 clones were sequenced
for each cell line analysed. The plasmid DNA was then purified
using a PI-100 Plasmid Purification System (Kurabo, Tokyo,
Japan) and sequenced using a Big Dye Terminator Cycle
Sequencing Ready Reaction Kit (Applied Biosystems) with an
ABI PRISM 3100 Genetic Analyzer (Applied Biosystems). For
direct sequencing, amplified bisulphite-PCR products were elec-
trophoresed in a 1% Seaplaque gel, excised and purified using a
PCR Purification System (Promega). The cycle sequencing reaction
was carried out as described above.
Flow cytometry
Jurkat and TALL1 cells were incubated for 96h under normoxic or
hypoxic (1% O2, 94% N2,5 %C O 2) conditions, harvested, fixed
with 90% ethanol and incubated for 30min with 2mgml
 1 RNase
(SIGMA). In addition, in some instances, TALL1 cells were
pretreated for 72h with 1mM 5-aza-dC. The cellular DNA was
then stained with 50mgml
 1 propidium iodide for 30min at 41C,
after which numbers of stained cells were determined using
fluorescent-activated cell sorting (FACS) on a Becton Dickinson
FACScaliber.
Chromatin immunoprecipitation analysis
Chromatin immunoprecipitation (ChIP) analysis was carried out
as described previously (Magdinier and Wolffe, 2001). Briefly,
DNA was crosslinked with chromatin by incubating cells in 1.0%
formaldehyde for 10min at 371C. The cells were then washed with
ice-cold PBS containing protease inhibitors and resuspended in
lysis buffer (1% SDS, 10mM EDTA, 50mM Tris–HCl, pH 8.0 and
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Figure 1 Expression of BNIP3 in haematopoietic tumour cell lines. (A) A panel of haematopoietic tumours cell lines was analysed for BNIP3 expression
by RT–PCR. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as an internal control for the integrity of the cDNA. Corresponding negative
controls (amplification without RT) are shown as RT-negative. Cell lines and tissues used are shown on the top. (B) Effect of hypoxia on expression of
BNIP3. Real-time PCR was carried out using cDNA from cells subjected to normoxic (20% O2, hypoxia ) or hypoxic (1% O2, hypoxiaþ) conditions for
24h. Signals normalised to GAPDH are shown on the Y-axis. Cell lines examined are shown below the columns. (C) Western blot analysis of HIF-1a and
BNIP3. Cells were incubated for 24h under normoxic (20% O2, hypoxia-) or hypoxic (1% O2, hypoxiaþ) conditions, after which the proteins were
separated by SDS–PAGE, and HIF-1a, BNIP3 and actin proteins were detected using appropriate antibodies.
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Figure 2 Analysis of BNIP3 methylation in a panel of haematopoietic
tumour cell lines. (A) CpG island of BNIP3; CpG sites are shown by vertical
bars. The region analysed by COBRA is shown by a solid bar. Exon 1 is
shown by a solid box on a solid line. The transcription start site is shown by
an arrow. (B) Aberrant methylation of BNIP3 in haematopoietic tumour
cell lines. Methylation of BNIP3 was examined using COBRA. Percentages
of methylated alleles are shown below the gels. M: methylated allele. (C)
Analysis of BNIP3 expression before and after treatment with 5-aza-dC.
Cell lines were treated for 96h with 2.0mM 5-aza-dC and then harvested,
after which RNA was extracted.
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Figure 3 Bisulphite-sequencing of BNIP3. (A) Representative results of bisulphite-sequencing. Amplified PCR products were purified from gels and then
directly sequenced. The cell lines examined are shown below the column; U, unmethylated CpG sites; M, methylated CpG sites. (B) Summary of bisulphite-
sequencing. Each circle represents a CpG dinucleotide. Methylation status: open circles, unmethylated; black circles, methylated. At least seven clones were
sequenced for each case. The CpG sites in the region analysed are indicated by vertical bar (top).
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sprotease inhibitor). The DNA within the chromatin was then
fragmented into 200–1000-bp segments by sonication, after which
immunoprecipitation was carried out for 16h at 41C with rotation
using antiacetylated histone H3 antibody (Upstate Biotechnologies,
Lake Placid, NY, USA) as a probe. The resultant immune
complexes were collected using protein A-agarose, and the DNA
was purified by phenol/chloroform extraction, precipitated with
ethanol and resuspended in water. About 1/100 of the precipitated
DNA was used for PCR. Real-time PCR was carried out using SYBR
Green sequence detection reagents (Applied Biosystems) as shown
above. The primers used were ChIP-F and ChIP-R; their sequences
and the PCR parameters are shown in Table 1. Each experiment
was repeated three times, and the average BNIP3/GAPDH signal
ratios are shown on the Y-axis.
RESULTS
We initially used RT–PCR to evaluate BNIP3 expression in a panel
of 20 haematopoietic tumour cell lines (Figure 1A). Expression of
BNIP3 was readily detectable in normal bone marrow and lymph
nodes, as well as in 15 of the cell lines tested. Of the remaining five
lines, two (TALL1 and Raji) expressed only negligible levels of
BNIP3, and three (SupT1, PEER and KHM1B) expressed none at
all. The earlier findings that under hypoxic conditions expression
of BNIP3 can be induced by the transcription factor HIF-1a
(Bruick, 2000; Guo et al, 2001; Sowter et al, 2001) prompted us to
evaluate the extent to which expression of BNIP3 in haematopoie-
tic tumour cell lines could be induced by hypoxia. Using real-time
PCR with cDNA prepared from Jurkat and SupT1 cells incubated
under hypoxic conditions, we found that hypoxia leads to
increased expression of BNIP3 in Jurkat cells but not in SupT1
cells (Figure 1B). When we carried out a Western blot analysis to
determine whether the absence of BNIP3 expression in SupT1 cells
was caused by impaired HIF-1a function, we found that hypoxia
induced HIF-1a expression in both Jurkat and Supt1 cells; thus, the
absence of BNIP3 was not caused by a HIF-1a deficiency
(Figure 1C).
Using Blast (http://www.ncbi.nlm.nih.gov/BLAST/) and CpG
island Searcher (http://www.uscnorris.com/cpgislands/), we found
that the 50 region of BNIP3 contains a CpG-rich region that
satisfies the criteria for a CpG island (CpG:GpC¼0.65,
GC%¼55%; Figure 2A). Then, to explore the role of BNIP3
methylation in haematopoietic tumours, we first used COBRA, a
semiquantitative methylation analysis, to examine the methylation
status of the region around the transcription start site in a panel of
haematopoietic tumour cell lines. Aberrant methylation of BNIP3
was detected in all five cell lines (SupT1, PEER, TALL1, Raji and
KHM1B) that either did not express BNIP3 at all or expressed it
only to a negligible degree (Figure 2B). By contrast, methylation of
BNIP3 was not detected in cell lines that expressed BNIP3,
although NAGL1 showed a low level of methylation but expressed
BNIP3, nevertheless. Notably, expression of BNIP3 could be
restored in the five methylated cell lines by treating them with
the methyltransferase inhibitor 5-aza-dC, which strongly suggests
that BNIP3 was epigenetically silenced by methylation in these
cells (Figure 2C).
To examine the methylation status of each CpG dinucleotide
within the BNIP3 CpG island, bisulphite-sequencing was
carried out in six cell lines (BALL1, CCRF-CEM, KHM1B,
SupT1, PEER and TALL1). In BALL1 and CCRF-CEM cells,
which COBRA showed to be unmethylated, virtually no methyla-
tion was detected within the region analysed (Figure 3A, B).
Conversely, in SupT1, PEER and TALL1 cells, which COBRA
showed to be highly methylated, virtually all of the CpG sites
within the region examined were methylated (Figure 3A, B).
KHM1B cells showed a more a heterogeneous methylation pattern
(Figure 3A, B).
To determine the extent to which the silencing of BNIP3 affected
hypoxia-mediated apoptosis, we examined the effect of 5-aza-dC
on the incidence hypoxia-mediated cell death among TALL1 cells,
which do not otherwise express BNIP3 as a result of the gene’s
methylation (Figure 4). We found that hypoxia readily induced cell
death among control Jurkat cells, which do express BNIP3. Among
TALL1 cells, pretreatment with 5-aza-dC had no significant effect
Jurkat TALL1
TALL1
5-aza-dC
Normoxia
Hypoxia
89% 12%
6% 1% 5%
46%
Figure 4 Restoration of hypoxia-mediated apoptosis by treatment with
5-aza-dC. TALL1 cells were treated with either mock or 1mM 5-aza-dC for
72h followed by incubation under normoxic or hypoxic conditions for
96h. Percentages of apoptotic cells were determined by flow cytometry.
The unmethylated Jurkat cell line served as a control.
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Figure 5 The role of histone deacetylation in silencing BNIP3 gene
expression. (A) Effects of DNA methyltransferase and/or histone
deacetylase inhibitor on the expression of BNIP3. SupT1 cells, which show
BNIP3 methylation, were treated with 0.2mM 5-aza-dC, 300nM TSA or
both. (B) Histone acetylation examined by ChIP followed by PCR.
Chromatin immunoprecipitation analysis was carried out using DNA
precipitated with antiacetylated histone H3 antibody; the bars show the
levels of histone acetylation determined by real-time-PCR normalised to
the GAPDH signal. The cell lines examined are indicated below.
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son the incidence of cell death under normoxic conditions. Under
hypoxic conditions, by contrast, significant numbers of apoptotic
cells were detected following pretreatment with 5-aza-dC, which is
indicative of the role played by epigenetic silencing of BNIP3 in
protecting cells from hypoxia-mediated apoptosis.
Methylation-dependent gene silencing is reportedly associated
with altered chromatin structure involving deacetylation of histone
(Jones and Baylin, 2002). Therefore, to assess the role of histone
deacetylation in the silencing of BNIP3, we treated the methylated
SupT1 cell line with 5-aza-dC and/or TSA, a histone deacetylase
inhibitor (Figure 5A). Treating the cells with a low dose (0.2mM)o f
5-aza-dC induced only a small amount of BNIP3 expression.
However, addition of TSA (300nM) to the 5-aza-dC had a
synergistic effect that markedly increased gene expression,
indicating a role for histone deacetylation in silencing of BNIP3
gene expression. We then examined the acetylation status of the
BNIP3 CpG island in more detail using ChIP assays with anti-
histone H3 antibody and found that acetylation of histone H3 in
the region around the transcription start site correlated directly
with gene expression and inversely with DNA methylation
(Figure 5B).
Finally, we determined the extent to which BNIP3 is methylated
in primary tumours by examining the methylation status of BNIP3
in a panel of primary leukaemia specimens. Using COBRA,
methylation of BNIP3 was detected in five of 34 (15%) ALL
specimens, in six of 35 (17%) AML specimens and in three of 14
(21%) multiple myeloma specimens (Figure 6A). These findings
were then confirmed by bisulphite-sequencing of the amplified
PCR products. All of the cases found to be methylated using
COBRA were found to be methylated at all of the CpG sites
examined (Figure 6B, C).
DISCUSSION
Tumour cells have an ability to escape apoptosis induced by
stresses such as DNA damage, growth factor withdrawal and
hypoxia. Resistance to hypoxia-induced apoptosis, in particular, is
an important factor in the progression of human neoplasias and in
the development of resistance to chemotherapy (Harris, 2002).
This is because selective elimination of apoptosis-sensitive cells
leads to expansion of cells that are more resistant to treatment and
thus contribute to tumour relapse (Schmaltz et al, 1998). In
contrast to solid tumours, little is known about how the cells of
haematopoietic tumours escape apoptosis induced by hypoxic
stress. In the current study, however, we have shown for the first
time that aberrant methylation of BNIP3 and histone deacetylation
are involved in silencing the gene in a subset of ALLs, AMLs and
multiple myelomas. This suggests that tumour cells that do not
express BNIP3 have a growth advantage related to their ability to
escape apoptosis induced by hypoxia.
BNIP3 was originally identified using a yeast two-hybrid screen
for proteins that bind to the adenoviral E1B 19-kDa protein (Boyd
et al, 1994). The protein contains a BH3 domain that induces
apoptosis (Yasuda et al, 1998) and a C-terminal transmembrane
domain that is required for both its mitochondrial localisation and
its proapoptotic activity (Chen et al, 1997, 1999; Yasuda et al,
1998); it has been suggested that BNIP3 mediates a necrosis-like
cell death by causing mitochondrial dysfunction (Harris, 2002).
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Figure 6 Analysis of BNIP3 methylation in a panel of primary haematopoietic tumours. (A) Methylation of BNIP3 examined using COBRA. Tumour type
is shown above the gels. Percentages of methylated alleles were calculated by densitometry and are shown below the gels. (B) Summary of bisulphite-
sequencing. Each circle represents a CpG dinucleotide. Methylation status: open circles, unmethylated; black circles, methylated. The cases examined are
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the transcriptional regulator HIF-1. BNIP3 is a principle target of
HIF-1, and the region containing BNIP3’s transcription start site
also contains HIF-1-binding sequences (Bruick, 2000; Sowter et al,
2001). It is noteworthy that because HIF-1 is involved in both
survival and apoptosis of tumour cells, abrogation of the apoptotic
pathway caused by silencing BNIP3 may enhance HIF-1-induced
survival signals within tumours.
Expression of BNIP3, which is induced by hypoxic stimuli (Guo
et al, 2001), has been detected in several human cancer cell lines
and cardiac myocytes subjected to hypoxia (Crow, 2002; Kubasiak
et al, 2002; Regula et al, 2002). In addition, Sowter et al (2003)
recently reported that BNIP3 is highly expressed in the hypoxic
regions of high-grade breast cancer. Future clinicopathological
analysis may clarify whether there is a specific phenotype for
tumours with BNIP3 methylation.
In the present study, we have shown that the silencing of BNIP3
is the result of DNA methylation of its 50 CpG island and histone
deacetylation. The fact that in methylated cell lines BNIP3
expression was restored by 5-aza-dC, a methyltransferase inhi-
bitor, confirms that inactivation of the gene was caused by DNA
methylation and not by, for example, the loss of transcription
factors. DNMT1 and DNMT3b are known to catalyse DNA
methylation in cancer cells (Rhee et al, 2002; Toyota et al, 2003);
the mechanism by which DNA methylation represses gene
expression is not fully understood, however, although histone
deacetylation reportedly plays a key role (Bird and Wolffe, 1999;
Cameron et al, 1999; Nguyen et al, 2001). Consistent with that
finding, our ChIP assays showed histone H3 to be deacetylated in
cell lines where BNIP3 is silent. It may be that dense methylation of
the BNIP3 CpG island attracts methyl-CpG-binding proteins, such
as MeCP2 and MBD2, which in turn recruit histone deacetylases
(Jones and Baylin, 2002). Recent reports also suggest that histone
methylation may be involved in DNA methylation-dependent gene
silencing (Fahrner et al, 2002; Nguyen et al, 2002; Kondo and Issa,
2003). Further study will be necessary to clarify the precise
mechanism by which CpG methylation silences BNIP3.
In summary, we have shown that DNA methylation and histone
deacetylation play key roles in silencing BNIP3 gene expression in
haematopoietic tumours. Inhibition of DNA methylation and histone
deacetylation act synergistically to induce gene expression, suggest-
ing that BNIP3 may be an effective molecular target for treating a
subset of haematopoietic tumours through activation of apoptosis by
methyltransferases and histone deacetylase inhibitors.
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